31 related articles for article (PubMed ID: 22329723)
1. RIPK1 polymorphisms and expression levels: impact on genetic susceptibility and clinical outcome of epithelial ovarian cancer.
Wang X; Deng K; Tao J; Zou J; Du Y; Dai L
Cancer Cell Int; 2023 Nov; 23(1):290. PubMed ID: 37996860
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
5. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.
Sebio A; Páez D; Salazar J; Berenguer-Llergo A; Paré-Brunet L; Lasa A; Del Río E; Tobeña M; Martín-Richard M; Baiget M; Barnadas A
Pharmacogenomics J; 2014 Jun; 14(3):256-62. PubMed ID: 23959273
[TBL] [Abstract][Full Text] [Related]
6. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Han JY; Shin ES; Lee YS; Ghang HY; Kim SY; Hwang JA; Kim JY; Lee JS
Pharmacogenomics J; 2013 Oct; 13(5):417-22. PubMed ID: 22664479
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
Zhang Y; Cao S; Zhuang C; Chen J; Chen X; Sun H; Lin S; Lin B
J Ovarian Res; 2021 Jun; 14(1):80. PubMed ID: 34148553
[TBL] [Abstract][Full Text] [Related]
8. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
Damia G; Broggini M
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.
Mlakar V; Huezo-Diaz Curtis P; Satyanarayana Uppugunduri CR; Krajinovic M; Ansari M
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618021
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Figg WD; Chau CH; Madan RA; Gulley JL; Gao R; Sissung TM; Spencer S; Beatson M; Aragon-Ching J; Steinberg SM; Dahut WL
Clin Genitourin Cancer; 2013 Sep; 11(3):229-37. PubMed ID: 23684781
[TBL] [Abstract][Full Text] [Related]
11. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
12. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
[TBL] [Abstract][Full Text] [Related]
13. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
Tang N; Lyu D; Zhang Y; Liu H
BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
[TBL] [Abstract][Full Text] [Related]
14. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
[TBL] [Abstract][Full Text] [Related]
15. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
[TBL] [Abstract][Full Text] [Related]
16. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]